CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC – Nizar Tannir
Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment’s enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation…